A multidisciplinary team (MDT) approach is considered the gold standard for the diagnosis and treatment of cancer.
The objectives of this webinar are to:
- Examine the role of MDTs in oncology clinical trials and how this role has evolved.
- Evaluate current oncology clinical trials involving an MDT for patient selection or treatment decisions.
- Discuss how the role of MDTs in clinical trials may change in the future.
Guest Speakers:
Harpreet Wasan
Harpreet Wasan is a Consultant and Reader in Medical Oncology at the Hammersmith Hospital, Imperial College London, UK.
Mladjan Protic
Mladjan Protic is the head of the department for Surgery at the Clinic for Surgical Oncology, Oncology Institute of Vojvodina, Sremska Kamenica, Serbia. He is also an Associate Professor for the Department of Surgery at the Medical Faculty of the University of Novi Sad, Serbia.
Brigitte Scott
Brigitte Scott is a Freelance Medical Writer and Editor at MarYas Editorial Services, Cowlinge, UK.
This webinar is part of a series, to watch “The Function and Impact of MDTs in Cancer Care”, click here
